EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tat-HSPE1 suppresses clear cell renal cell carcinoma growth through lysosome-dependent cell death

Lin Zhang, Weiyuan Li, Min Liu, Dong Li, Guang-Zhi Jin

Frontiers in Pharmacology · 01.05.2026 · 17

DOI: 10.3389/fphar.2026.1822208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.05.2026. Verfasst von Lin Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer; however, first-line therapeutic agents show limited efficacy in patients with advanced disease. Bioactive peptides have emerged as promising candidates for anticancer therapy. In this study, a novel peptide derived from Heat Shock Protein Family E Member 1 (HSPE1) was identified by peptidomics analysis of human ccRCC tissues and paired adjacent normal tissues. We then engineered a novel fusion peptide designated Tat-HSPE1. Tat-HSPE1 selectively induced in vitro cell death in ccRCC cells while exerting minimal cytotoxic effects on normal epithelial cells and other tumor cell types. Analyses on the potential mechanism revealed that Tat-HSPE1 induced DNA damage, caspase-independent apoptosis, and lysosomal membrane permeabilization. Following cellular uptake, Tat-HSPE1 preferentially accumulated within the nucleolar compartment, where it interacted with CTTNBP2NL, a newly identified negative regulator of autophagy. This interaction promoted the translocation of CTTNBP2NL from the nucleus to the cytoplasm, facilitating the activation of autophagic processes. Furthermore, in vivo experiments demonstrated that Tat-HSPE1 significantly suppressed xenograft tumor growth. These findings indicate that Tat-HSPE1 represents a promising peptide-based therapeutic candidate for the treatment of ccRCC.

Schlagwörter

Stichwörter der Autor:innen

CTTNBP2NLautophagyheat shock proteinslysosomal membrane permeabilization (lmp)peptiderenal cancer

Autor:innen und Institutionen

  • Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pathology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Zitieren

APA

Zhang, L., Li, W., Liu, M., Li, D., & Jin, G. Z. (2026). Tat-HSPE1 suppresses clear cell renal cell carcinoma growth through lysosome-dependent cell death. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1822208

Vancouver

Zhang L, Li W, Liu M, Li D, Jin GZ. Tat-HSPE1 suppresses clear cell renal cell carcinoma growth through lysosome-dependent cell death. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1822208

BibTeX
@article{Zhang2026,
  author = {Zhang, Lin and Li, Weiyuan and Liu, Min and Li, Dong and Jin, Guang-Zhi},
  title = {Tat-HSPE1 suppresses clear cell renal cell carcinoma growth through lysosome-dependent cell death},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1822208}
}
Kostenlos starten →